Last 39 quarters of trend data · Healthcare · Diagnostics & Lab Testing
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 77.51 | 153.15 | — | — | 24.09 | 92.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +66.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.80 | 8.21 | 4.78 | 5.84 | 6.68 | 10.37 | 10.16 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -20.8% | -53.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 12.67 | 14.14 | 8.52 | 8.51 | 13.55 | 18.79 | 16.28 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -24.8% | -47.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 138.64 | — | 43.55 | 56.05 | 49.26 | 40.62 | 312.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | -86.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 41.28 | 80.82 | 35.88 | 112.64 | 19.96 | 57.74 | 72.49 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +40.0% | -50.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 148.81 | 80.82 | 139.38 | 95.81 | 19.83 | 57.25 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +41.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.4% | 66.2% | 68.1% | 65.4% | 75.4% | 68.0% | 62.7% | 47.2% | 54.4% | 43.7% | 37.5% | 32.4% | 53.6% | 50.0% | 47.8% | 63.4% | 61.5% | 61.9% | 48.7% | 47.5% | 48.1% |
| — | -2.7% | +8.7% | +38.6% | +38.6% | +55.7% | +67.0% | +45.8% | +1.4% | -12.6% | -21.4% | -49.0% | -12.8% | -19.2% | -2.0% | +33.4% | +27.8% | +28.6% | -1.2% | -3.9% | -1.9% | |
| Operating Margin | 5.6% | 7.0% | 10.2% | 2.4% | 30.2% | 15.1% | 9.9% | -47.9% | -28.5% | -59.9% | 67.0% | -114.3% | 65.9% | 59.3% | 60.4% | 56.1% | 45.0% | 43.6% | 32.0% | 28.1% | 32.0% |
| — | -53.4% | +3.0% | +105.1% | +205.9% | +125.1% | -85.2% | +58.1% | -143.3% | -200.9% | +11.0% | -303.9% | +46.5% | +36.1% | +88.7% | +99.8% | +40.6% | +33.7% | +0.7% | -16.4% | -8.3% | |
| Net Margin | -66.2% | 5.5% | -0.2% | -0.2% | 28.0% | 11.2% | -39.6% | -84.8% | -28.4% | -66.6% | -66.2% | -137.6% | 50.7% | 44.3% | 44.2% | 22.1% | 19.5% | -0.8% | -1.3% | 7.8% | -4.4% |
| — | -50.6% | +99.4% | +99.7% | +198.4% | +116.8% | +40.2% | +38.4% | -156.1% | -250.5% | -249.6% | -721.4% | +159.7% | +5455.8% | +3592.8% | +182.7% | +542.7% | -109.3% | -107.6% | -53.3% | -123.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -93.2% | 2.5% | -0.1% | -0.1% | 15.5% | 5.2% | -15.9% | — | — | — | — | -28.4% | 6.6% | 5.1% | 5.0% | 2.0% | 2.2% | -0.1% | -0.2% | 1.1% | -0.7% |
| — | -52.6% | +99.3% | — | — | — | — | — | — | — | — | -1498.2% | +195.0% | +5731.4% | +2702.2% | +78.6% | +423.4% | -106.8% | -107.3% | -59.0% | -121.0% | |
| ROA | -73.2% | 1.2% | -0.1% | -0.0% | 7.8% | 2.5% | -11.5% | -32.3% | -10.7% | — | — | — | 1.6% | 1.3% | 1.4% | 0.5% | 0.5% | -0.0% | -0.0% | 0.3% | -0.2% |
| — | -51.1% | +99.5% | +99.9% | +172.3% | — | — | — | -753.7% | — | — | — | +209.6% | +6142.2% | +3037.8% | +87.0% | +432.1% | -107.1% | -107.3% | -58.5% | -121.0% | |
| ROIC | 21.3% | 7.3% | 7.3% | 2.2% | 42.7% | 16.1% | — | — | — | — | — | -4.8% | 1.8% | 1.5% | 1.5% | 1.0% | 1.0% | 0.9% | 0.9% | 0.8% | 0.9% |
| — | -54.6% | — | — | — | — | — | — | — | — | — | -568.3% | +84.5% | +61.9% | +61.0% | +34.4% | +4.4% | -0.3% | -2.7% | -28.4% | -22.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.66 | 0.11 | 0.76 | 0.73 | 0.66 | 0.89 | 0.93 | — | — | — | — | — | 2.82 | 2.41 | 2.52 | 2.49 | 3.16 | 2.88 | 3.05 | 3.03 | 3.10 |
| — | -87.8% | -17.4% | — | — | — | — | — | — | — | — | — | -10.7% | -16.3% | -17.5% | -17.9% | +1.8% | -6.8% | +3.1% | -1.7% | +9.6% | |
| Debt / EBITDA | 5.60 | 2.67 | 13.52 | 41.65 | 4.09 | 11.38 | 17.17 | — | — | — | — | — | 22.75 | 22.70 | 23.56 | 29.19 | 33.37 | 32.14 | 34.34 | 38.26 | 33.47 |
| — | -76.5% | -21.3% | — | — | — | — | — | — | — | — | — | -31.8% | -29.4% | -31.4% | -23.7% | -0.3% | -9.6% | +11.3% | +26.0% | +22.2% | |
| Current Ratio | 7.85 | 6.71 | 5.53 | 7.05 | 7.85 | 9.93 | 9.24 | 1.05 | 1.30 | — | — | — | 0.72 | 0.45 | 0.74 | 0.67 | 0.82 | 0.75 | 1.07 | 1.74 | 1.23 |
| — | -32.4% | -40.2% | +569.1% | +501.8% | — | — | — | +82.0% | — | — | — | -12.6% | -39.6% | -30.3% | -61.4% | -33.2% | -43.0% | +96.8% | +235.9% | +200.2% | |
| Quick Ratio | 7.85 | 5.84 | 4.88 | 7.05 | 7.85 | 9.36 | 8.79 | 0.83 | 1.06 | — | — | — | 0.72 | 0.45 | 0.74 | 0.67 | 0.82 | 0.75 | 1.07 | 1.74 | 1.23 |
| — | -37.5% | -44.5% | +750.7% | +637.0% | — | — | — | +48.6% | — | — | — | -12.6% | -39.6% | -30.3% | -61.4% | -33.2% | -43.0% | +96.8% | +235.9% | +200.2% | |
| Interest Coverage | -0.20 | 2.82 | 0.93 | 0.95 | 8.22 | 2.80 | -2.74 | -7.03 | -2.79 | -4.41 | -3.84 | -10.95 | — | 4.58 | 4.33 | 8.27 | 2.10 | 1.97 | 0.77 | 1.43 | 1.81 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 39 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CAI stock.
Caris Life Sciences, Inc.'s current P/E is 77.5x. The average P/E over the last 2 quarters is 88.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Caris Life Sciences, Inc.'s current operating margin is 5.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Caris Life Sciences, Inc.'s business trajectory between earnings reports.